bproulx

Bob is currently CEO at Imagion Biosystems developing an early cancer detection technology with more than 25 years experience commercializing new technologies.

[bproulx @bproulx]

For those that couldn’t make our AGM yesterday, we have recordings of our chairman’s address and our Q&A session including shareholder questions available here: https://t.co/YH64VZRgsT

[bproulx @bproulx]

Our two scientific posters related to the advancements in @imagionbio's ovarian cancer detection program were presented at the #AACR23 meeting today and are now available for download.
Access here: https://t.co/hT7V1UoPcX #OvarianCancer #Medicalmaging $IBX

[bproulx @bproulx]

We are pleased to see Pitt Street Research has published an updated report on @imagionbio. This detailed report includes close examinations of the company’s business and investment potential. Read the full report here: https://t.co/6w4gOormGW
#MedicalImaging #MarketReport $IBX

[bproulx @bproulx]

I was pleased to be a guest on @PodcastFear this weekend discussing @Imagionbio's pursuit of better, more precise imaging solutions to detect cancers, while providing an update of our #IBX Phase I clinical trial: https://t.co/c8feYSCp5r

[bproulx @bproulx]

Recently, I wrote for @AsiaBioSpectrum on the application of nanoparticles in healthcare, changing the way we prevent, diagnose, and treat life-threatening diseases. Review more about the work @imagionBiosystems is doing in cancer imaging: https://t.co/kc7aEOD9dh

[bproulx @bproulx]

We're looking for a motivated and experienced Director of Quality Assurance to join our growing team in our new San Diego facility. To apply or learn more about this position visit: https://t.co/VuLxf919ef #Biotechjobs #qualityassurance

[bproulx @bproulx]

Check out my interview with @Edison_Inv_Res where we discuss the #nanotechnology behind @imagionbio's bio-imaging #MagSense technology and how we hope to make a big difference in #EarlyCancerDetection. Watch here: https://t.co/f1E2avrLgd #IBX

[bproulx @bproulx]

@mhtxscientifics 👍 #MagSense

[bproulx @bproulx]

@imagionbio @COBLH @MonashUni Very proud of the work being done and the progress being made by @imagion $IBX to advance our #MagSense technology.

[bproulx @bproulx]

Check out my recent interview with The Market Herald - https://t.co/CWbUFF0yhD

[bproulx @bproulx]

Very happy to see one of Imagion's Board members taking the lead in combating the COVID-19 pandemic. David Ludvigson, CEO of Nanomix is working on a rapid Point-of-Care test for the virus. Good luck to Nanomix! #covid19testing https://t.co/mJtQYCIO3o

[bproulx @bproulx]

@imagionbio @leannee_daly @ImagingCoE Awesome to see the @imagionbio team making an impact on the medical imaging community! Thanks @leannee_daly

[bproulx @bproulx]

Here’s my most recent podcast interview with @finfeed - https://t.co/AB0zKlIqz7

[bproulx @bproulx]

@imagionbio @nextbiotech Great to see the #MagSense technology getting some attention as we try to improve medical imaging for the early detection of cancer.

[bproulx @bproulx]

Check out my interview with Scott Power from the @morgansAU podcast to discuss how Imagion's #MagSense could change the #healthcare industry, the company's recent progress, and Imagion’s next steps towards a clinical study https://t.co/MeeC75WzK9 #ASX

[bproulx @bproulx]

Thanks to @proactive_au for the video interview https://t.co/61oWWLjpvH to help highlight Imagion's recent announcement about our technology being designated a "Breakthrough Device"!

[bproulx @bproulx]

Super excited by the news we received this week @imagionbio. @US_FDA has designated our MagSense technology as a “Breakthrough Device”! Very cool.

[bproulx @bproulx]

Check out my video-taped interview with @proactive_au https://t.co/mbDbjOeneI

[bproulx @bproulx]

Just finished reading ‘Bad Blood’ the story of fraud and deception perpetrated by Theranos. Incredible story of lies and manipulation in pursuit of fame and money. Glad science and truth won. Well done Carreyrou.

[bproulx @bproulx]

A better answer is that the brand position 'Made in America' resonates with the US consumer and HD will remain loyal to that brand. 'MiA' may no longer apply in foreign markets and selling motorcycles at reduced margins overseas due to tariffs won't resonate with shareholders.